RAY1225
Phase 3Small molecule
RAY1225 is one of 169 small molecule programs targeting Function. It is currently in Phase 3.
6
Indications
11
Total Trials
8
Active Trials
168
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
190 competitors in Obesity
#DrugCompanyPhaseTrials
1Cagrilintide
Novo NordiskPhase 3
Maridebart Cafraglutide
AmgenPhase 3
Decadron
AAspen Global Incorporated
Phase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
IBI362
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
RAY1225
GGuangdong Raynovent Biotech Co., Ltd
Phase 3
Gemtesa
Sumitomo Pharma America, Inc.Phase 3
Mibavademab
RegeneronPhase 3
Elecoglipron
AstraZenecaPhase 3
Aleniglipron
GGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 2 Diabetes3 trials
Function2 trials
3 more indications
Basic Science1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RAY1225. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details